Adult acute lymphocytic leukemia. Introduction and questions related to current programs.
Significant progress has been made during the past 30 years in understanding the biology of adult acute lymphocytic leukemia and in treating the disease. This article lists some of the questions related to the current treatment programs for ALL and notes the remaining articles in this issue that address those questions.
Kantarjian
H M
HM
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. hkantarj@mdanderson.org
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050676:Core Binding Factor Alpha 2 Subunit; D006801:Humans; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome; D000097764:ETS Translocation Variant 6 Protein
D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein